A First-In-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination With Erlotinib in Advanced Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-1418
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

A Phase I First-In-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients With Advanced Cancer

Clinical Cancer Research
Cancer ResearchOncology
2012English

A Phase I Trial Investigating Pulsatile Erlotinib in Combination With Gemcitabine and Oxaliplatin in Advanced Biliary Tract Cancers

Investigational New Drugs
OncologyPharmacology
2016English

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2006English

A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination With Erlotinib in Patients With Advanced Solid Tumors

Oncologist
Cancer ResearchMedicineOncology
2017English

Erratum To: A Phase I Dose-Escalation Study of Selumetinib in Combination With Erlotinib or Temsirolimus in Patients With Advanced Solid Tumors

Investigational New Drugs
OncologyPharmacology
2017English

A Phase I First-In-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2015English

A Phase I Trial of Combination Trastuzumab, Lapatinib, and Bevacizumab in Patients With Advanced Cancer

Investigational New Drugs
OncologyPharmacology
2014English

A Phase I Study of Weekly Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

Oncologist
Cancer ResearchMedicineOncology
2010English

First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy